Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02058199 · ClinicalTrials.gov registry record · Phase 1
Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery
A Phase 1 study, sponsored by State University of New York - Upstate Medical University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02058199: Clinical Trial Phase 1 study, sponsored by State University of New York - Upstate Medical University.
NCT02058199 is a Phase 1 study that was terminated before completion, run by State University of New York - Upstate Medical University. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02058199, a Phase 1 study, was terminated before completion, sponsored by State University of New York - Upstate Medical University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The investigators are attempting to compare the anticoagulant (blood thinning) effects of a recently FDA approved medication, Rivaroxaban, in people who have undergone gastric bypass surgery to people who have not had this surgery. It is thought that gastric bypass may alter the absorption of this medication, but this has not been previously studied. The investigators will study the anticoagulant effect of rivaroxaban in healthy volunteers who are in one of four groups 1. Non obese people who have not had a gastric bypass. 2. Obese people who have not had a gastric bypass 3. People who have had a gastric bypass 4. People who are planning to undergo gastric bypass surgery in the near future who are willing to be studied before and after the bypass. The study will involve taking a single low dose of rivaroxaban and multiple blood samples will be taken over the next 24 hours and the effect of rivaroxaban on blood clotting will be measured using the prothrombin time and an anti-factor Xa assay. The effects of rivaroxaban will be compared between the different groups.
Primary Outcome
pharmacodynamic
Interventions
- DRUG rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Why NCT02058199 stopped before completion
NCT02058199 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which rivaroxaban is the first listed.
NCT02058199 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02058199 about?
NCT02058199 is a clinical study titled "Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery". The investigators are attempting to compare the anticoagulant (blood thinning) effects of a recently FDA approved medication, Rivaroxaban, in people who have undergone gastric bypass surgery to people who have not had this surgery. It is thought that gastric bypass may alter the absorption of this m...
What is the current status of trial NCT02058199?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2014-12. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02058199?
The interventions under investigation include: rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT02058199?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02058199's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia